Abstract:Abstract Background and purpose: Abnormal glucose metabolism status (AGM), including prediabetes and diabetes mellitus (DM) have been reported to be an important predictor of poor functional outcome in patients experiencing acute ischemic stroke (AIS). However, conclusions of recent studies are inconsistent about which AGM status increases the risk of post-thrombolysis early neurological deterioration (END). The purpose of this study was to evaluate the impact of AGM status on the risk of post-thrombolysis early neurological outcomes. We further investigated the influence of previous glucose control of diabetic patients on the post-thrombolysis early neurological outcomes evaluation. Methods: Prediabetes was identified as glycosylated hemoglobin (HbAlc) (%) level within the range of 5.7%-6.4%, and diabetes mellitus (DM) was diagnosed based on prior history of diabetes or an HbAlc≥6.5% and patients with HbAlc less than 5.7% were classified as normal glucose metabolism (NGM). Diabetic patients with good PGC had HbAlc <7%, diabetic patients with poor PGC had HbAlc≥7%. END was defined as a National Institutes of Health Stroke Scale Score (NIHSS) ≥ 4, ENI was defined as a ≥4-point decrease in NIHSS score or a complete resolution of neurological deficits, between the time of admission and 24 hours after IV-rtPA. Results In total, 261 (32.7%) patients were diagnosed with prediabetes, 91 (11.4%) patients were DM had good PGC and 186 (23.3%) patients were DM had poor PGC. After adjusted for confounders, in model 1, DM with poor PGC associated with the increased risk of post-thrombolysis END and poor functional outcome at discharge (OR, 2.09; 95% CI, 1.220-3.579; P=0.007) (OR, 1.91; 95% CI, 1.165-3.133; P=0.010), both prediabetes and DM with poor PGC were less likely to experience post-thrombolysis ENI (OR, 0.58; 95% CI, 0.377-0.907; P=0.016) (OR, 0.43; 95% CI, 0.255-0.71; P=0.001); in model 2, further adjusted for admission hyperglycemia, the presence of diabetes and DM with poor PGC was still independently related to post-thrombolysis ENI (OR, 0.62; 95% CI, 0.400-0.969; P=0.036) (OR, 0.51; 95% CI, 0.282-0.923; P=0.026). Conclusion Prediabetes and DM with poor PGC might be two abnormal blood glucose metabolism states that affects post-thrombolysis early neurological outcome in AIS patients.

Rapid glycemic regulation in poorly controlled patients living with diabetes, a new associated factor in the pathophysiology of Charcot's acute neuroarthropathy

Trends in the relation between hyperglycemia correction and active Charcot neuroarthropathy: results from the EPICHAR study

Charcot Pathogenesis: A Study of In Vivo Gene Expression

Current concepts underlying the pathophysiology of acute Charcot neuroarthropathy in the diabetic foot and ankle

Developing an evidence-based clinical pathway for the assessment, diagnosis and management of acute Charcot Neuro-Arthropathy: a systematic review

Association of Anatomical Location of Neuroarthropathic (Charcot’s) Destruction with Age-and Sex-Matched Bone Mineral Density Reduction

Animal model detects early pathologic changes of Charcot neuropathic arthropathy

Charcot neuroarthropathy of the knee due to idiopathic sensory peripheral neuropathy

Impact of glucagon-like peptide-1 receptor agonists on axonal function in diabetic peripheral neuropathy

Early Treatment of Acute Stage 0/1 Diabetic Charcot Foot Can Avoid Major Amputations at One Year

Five cases of acute painful neuropathy induced by rapid glycaemic control with insulin and literature review

Charcot neuroarthropathy in diabetic patients in Texas

Biomarkers for Early Detection of Charcot Arthropathy: A Prospective Study on Type 2 Diabetes Patients with Severe Neuropathy

Acute worsening of microvascular complications of diabetes mellitus during rapid glycemic control: The pathobiology and therapeutic implications

Charcot Foot: An Update on Diagnosis, Treatment, and Areas of Uncertainty

Factors associated with the development of recurrent and contralateral Charcot neuroarthropathy in individuals with diabetes mellitus: A scoping review

Diabetic Charcot neuroarthropathy: A threat to both limb and life

Measuring of Advanced Glycation End Products in Acute Stroke Care: Skin Autofluorescence as a Predictor of Ischemic Stroke Outcome in Patients with Diabetes Mellitus

Impact of abnormal glucose metabolism on the early neurological outcome in acute ischemic stroke patients treated with intravenous thrombolysis

Evaluation of the Impact of Advanced Glycation End-Products on Peripheral Neuropathy Outcomes in Type 2 Diabetes

Advanced glycation end-products are associated with diabetic neuropathy in young adults with type 1 diabetes